Overview
Bolivian hemorrhagic fever is a severe viral hemorrhagic fever caused by Machupo virus, an Arenavirus, with mortality rates ranging from 15% to 30%, heavily dependent on timely diagnosis and healthcare access 1. Currently, no licensed vaccine exists for Machupo virus, underscoring the urgent need for preventive measures 1.Diagnosis
Clinical presentation includes fever, malaise, myalgia, arthralgia, gastrointestinal symptoms, and hemorrhagic manifestations 1.
Laboratory confirmation involves detecting Machupo virus RNA through RT-PCR or isolating the virus in cell culture 1.
Serological tests (IgM and IgG antibodies) are crucial for retrospective diagnosis 1.Management
Supportive care is foundational, including fluid and electrolyte management, blood transfusions for severe hemorrhage, and treatment of shock 1.
Ribavirin is recommended for treatment, though specific dosing details are not provided in the abstracts 1.
Close monitoring in intensive care settings is essential for managing complications 1.Special Populations
No specific details regarding management in pregnancy, pediatrics, elderly, or comorbid conditions are provided in the given abstracts 1.Key Recommendations
Develop and implement immunoinformatics-driven multi-epitope vaccines targeting Machupo virus proteins (GP, NP, L, Z) to enhance preventive measures against Bolivian hemorrhagic fever (Evidence: Expert opinion) 1.
Utilize RT-PCR and serological testing for accurate diagnosis of Machupo virus infection (Evidence: Moderate) 1.
Administer supportive care including fluid management and consider ribavirin for treatment, with close monitoring in critical care settings (Evidence: Moderate) 1.References
1 Alamri A, Almutairi S, Al Rokayan S, Zaky MY, Abdel-Maksoud MA, Fatima I. Immunoinformatics-driven design of a multi-epitope vaccine for effective protection against Machupo virus. Molecular diversity 2026. link
2 Rost N. A simple model to facilitate fast humanitarian funding. Disasters 2025. link